Benefit of a second opinion for lung cancer: no recurrent disease, but infection.
Department of Pulmonary Diseases, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. r.schook@vumc.nl
Romane M
RM
Schook
Schook M
SM
Romane
Egbert F
EF
Smit
Smit F
SF
Egbert
Pieter E
PE
Postmus
Postmus E
PE
Pieter
Koen J
KJ
Hartemink
Hartemink J
HJ
Koen
Marinus A
MA
Paul
Paul A
PA
Marinus
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000068437:Pemetrexed; D011182:Postoperative Care; D011379:Prognosis; D012017:Referral and Consultation / Q000706:statistics & numerical data*
D000890:Anti-Infective Agents; D005971:Glutamates; D000068437:Pemetrexed; D002939:Ciprofloxacin; D006147:Guanine; D005047:Etoposide; D002945:Cisplatin